ArticleNature2023
Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates.
Open access · hybridFull text read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
31.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 109 citations in OpenAlex.
- Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model.The New England journal of medicine · 2025Trial
- Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Therapeutic approaches against dengue virus: current status of vaccines, antivirals, and monoclonal antibodies.Emerging microbes & infections · 2026Review
- Conformational Dynamics of Viral Protease Precursors in Maturation, Inhibition, and Drug-Resistance Development.Viruses · 2026Review
- Atlastin-2-mediated endoplasmic reticulum membrane tethering is critical for flavivirus replication.PLoS biology · 2026Article
- Viral Dynamic Model-Informed Dose Selection of Mosnodenvir Prophylaxis against DENV-3 in a Controlled Human Infection Model.Clinical pharmacology and therapeutics · 2026Article
- Quantum Pharmacophore-Based Virtual Screening Enables Prospective Discovery of Chemotype-Diverse Dengue NS5 Inhibitors.Journal of chemical information and modeling · 2026Article
- Nanoparticle vaccine formulations for dengue virus.RSC pharmaceutics · 2026Review
- Article
- An orthoflavivirus inhibitor targeting multifunctional NS2A protein, a previously unidentified target.PLoS pathogens · 2026Article
- Japanese encephalitis virus orchestrates GLUT4-mediated glucose metabolism to potentiate viral replication via insulin receptor signaling.PLoS pathogens · 2026Article
- The Flavivirus NS3 Protein: Its Multifaceted Roles and Therapeutic Potential.Journal of medical virology · 2026Review
- A genus-wide interaction atlas across NS4B orthologues identifies a conserved role for UFMylation in orthoflavivirus replication.Nature communications · 2026Article
- Inhibition of dengue virus type 2 by hypericin mediated through viral envelope protein interaction.Virology journal · 2026Article
- Cryo-electron tomography reveals coupled flavivirus replication, budding and maturation.Nature communications · 2026Article
- Design of a novel epitope-based tetravalent subunit vaccine against dengue virus: An immunoinformatic approach.PloS one · 2026Article
- Antiviral Strategies Against Dengue Virus: Recent Insights into Compounds Targeting Viral and Host Factors.Current topics in microbiology and immunology · 2026Review
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- Hepatitis E Virus ORF1 Polyprotein Harbors a Pocket-Like Cavity That Is Vital for Virus Replication and Represents a Novel Antiviral Target.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A dual-reporter HCoV-OC43 for coronavirus biology and countermeasure development.Antiviral research · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
44 authors at 10 institutions in 7 countries.
Olivia GoethalsJanssen Global Public Health, Janssen Pharmaceutica NV, Beerse, Belgium.ORCID http://orcid.org/0000-0001-8214-8989
Suzanne J F KapteinDepartment of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-7935-0219
Bart KesteleynJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.ORCID http://orcid.org/0000-0003-3862-4153
Jean-François BonfantiJanssen Infectious Diseases Discovery, Janssen-Cilag, Val de Reuil, France.ORCID http://orcid.org/0000-0002-2107-8857
Liesbeth Van WesenbeeckJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Dorothée BardiotCistim Leuven vzw, Leuven, Belgium.
Ernst J VerschoorDepartment of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.ORCID http://orcid.org/0000-0003-0912-2074
Babs E VerstrepenDepartment of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.ORCID http://orcid.org/0000-0002-4666-0798
Zahra FagrouchDepartment of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.
J Robert PutnakViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Dominik KiemelHeidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany.
Oliver AckaertJanssen Clinical Pharmacology and Pharmacometrics, Janssen Pharmaceutica NV, Beerse, Belgium.ORCID http://orcid.org/0000-0002-5908-5200
Roel StraetemansStatistics and Decision Sciences, Janssen Pharmaceutica NV, Beerse, Belgium.
Sophie Lachau-DurandJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Peggy GeluykensJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Marjolein CrabbeStatistics and Decision Sciences, Janssen Pharmaceutica NV, Beerse, Belgium.
Kim ThysJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Bart StoopsJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Oliver LenzJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Lotke TambuyzerJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.ORCID http://orcid.org/0000-0002-1705-3753
Sandra De MeyerJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Kai DallmeierDepartment of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-8117-9166
Michael K McCrackenViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Gregory D GromowskiViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Wiriya RutvisuttinuntViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Richard G JarmanViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0002-5765-0173
Nicos KarasavvasViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Franck TouretUnité des Virus Émergents, Aix-Marseille Université-IRD 190-Inserm 1207, Marseille, France.ORCID http://orcid.org/0000-0002-4734-2249
Gilles QueratUnité des Virus Émergents, Aix-Marseille Université-IRD 190-Inserm 1207, Marseille, France.
Xavier de LamballerieUnité des Virus Émergents, Aix-Marseille Université-IRD 190-Inserm 1207, Marseille, France.ORCID http://orcid.org/0000-0001-7895-2720
Laurent Chatel-ChaixHeidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7390-8250
Gregg N MilliganSealy Institute for Vaccine Sciences, The University of Texas Medical Branch Health, Galveston, TX, USA.
David W C BeasleySealy Institute for Vaccine Sciences, The University of Texas Medical Branch Health, Galveston, TX, USA.
Nigel BourneSealy Institute for Vaccine Sciences, The University of Texas Medical Branch Health, Galveston, TX, USA.
Alan D T BarrettSealy Institute for Vaccine Sciences, The University of Texas Medical Branch Health, Galveston, TX, USA.
Arnaud MarchandCistim Leuven vzw, Leuven, Belgium.
Tim H M JonckersJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Pierre RaboissonJanssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Kenny SimmenJohnson & Johnson Innovation, London, UK.
Patrick ChaltinCistim Leuven vzw, Leuven, Belgium.
Ralf BartenschlagerHeidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5601-9307
Willy M BogersDepartment of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.ORCID http://orcid.org/0000-0002-4563-8513
Johan NeytsDepartment of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-0033-7514
Marnix Van LoockJanssen Global Public Health, Janssen Pharmaceutica NV, Beerse, Belgium. mvloock@its.jnj.com.ORCID http://orcid.org/0000-0003-4151-4588
Janssen (Belgium) · BEWalter Reed Army Institute of Research · USBiomedical Primate Research Centre · NLThe University of Texas Medical Branch at Galveston · USHeidelberg University · DEInserm · FRKU Leuven · BERega Institute for Medical Research · BEJanssen (France) · FRJohnson & Johnson (United Kingdom) · GB
Funding
Wellcome Trust
Abstract
Dengue is a major health threat and the number of symptomatic infections caused by the four dengue serotypes is estimated to be 96 million
Indexed as
Antiviral AgentsDengueDengue VirusPrimatesViral Nonstructural ProteinsAnimalsClinical Trials, Phase I as TopicDEAD-box RNA HelicasesDose-Response Relationship, DrugDrug Resistance, ViralHumansHydrocarbons, HalogenatedIndolesIn Vitro TechniquesMembrane ProteinsMiceAntiviral AgentsDEAD-box RNA HelicasesHydrocarbons, HalogenatedIndolesJNJ-1802Membrane ProteinsNS3 protein, flavivirusNS4B protein, Dengue virusNucleoside-TriphosphataseSerine EndopeptidasesViral Nonstructural ProteinsViral Proteases
Identifiers
What OpenQuestion holds
Textfull text, public
LicenceCC BY
measurements read193
identifiers read1
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.